Trial Profile
A multicenter, open-label continuation trial evaluating the tolerability and activity of FK228 [romidepsin] in patients that have completed a prior clinical study with FK228
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2019
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Prostate cancer; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Celgene Corporation; Gloucester Pharmaceuticals
- 13 Aug 2008 Gloucester Pharmaceuticals reported as trial sponsor and affiliateby ClinicalTrials.gov.
- 13 Aug 2008 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 11 May 2007 New trial record.